Does Cannabis Affect Fertility? Understanding the Hormonal and Reproductive Impact

Key Takeaways

Cannabis disrupts fertility across both sexes through direct interference with reproductive hormone signaling and the cellular processes essential to conception.

• Cannabis reduces sperm quality and count: Men who use marijuana show 28% lower sperm concentration, decreased motility, and abnormal morphology, with measurable effects emerging 5–6 weeks after regular use begins.

• THC disrupts female ovulation and egg quality: Women who use cannabis experience delayed ovulation by 1.7–3.5 days, higher rates of anovulatory cycles, and a 9% increase in chromosomal abnormalities in eggs.

• Pregnancy outcomes worsen with cannabis use: Prenatal exposure doubles the risk of low birth weight, increases preterm delivery by 28%, and produces lasting neurodevelopmental consequences in children.

• IVF success rates decline significantly: THC-positive patients retrieve 25% fewer eggs, achieve embryo euploidy rates of only 60% compared to 67% in non-users, and face double the probability of pregnancy loss.

• Complete cessation is recommended before conception: Major medical organizations advise discontinuing cannabis use at least 74–90 days before attempting conception, allowing sufficient time for reproductive recovery.

The reproductive system retains the capacity to recover following cannabis cessation, yet the accumulated evidence demonstrates that continued use during the conception period materially compromises fertility outcomes and elevates risk for both parents and their future children.

An estimated 224 million individuals worldwide currently use cannabis1 — a substance that now ranks as the most commonly used illicit drug globally2. Prevalence has climbed from 3.9% in 2013 to 4.6% in 20231, and THC concentrations in commercial cannabis products have risen sharply, from approximately 3% in the 1980s to around 15% by 20203. These epidemiological and pharmacological shifts make it clinically necessary to examine whether cannabis affects reproductive hormones in both sexes and what its broader impact on fertility may be. Current evidence suggests that cannabis use may adversely affect several male and female reproductive outcomes, although the strength of association varies across hormones, semen parameters, ovulation, oocyte quality, pregnancy outcomes, and assisted reproduction studies. This broader shift in psychoactive substance exposure also connects with Emerging Toxicological Threats in the U.S.: Xylazine, Nitazenes, Novel Sedatives, Synthetic Cannabinoids, Fentanyl Analogues, and Toxic Mushrooms, which explains how changing drug markets are reshaping modern toxicology.

How Cannabis Works in the Body

Active Compounds in Cannabis (THC and CBD)

According to the cited pharmacological review, Cannabis sativa has been reported to contain more than 538 known chemical compounds, approximately 100 of which are classified as cannabinoids4. These cannabinoids are aryl-substituted meroterpenes, yet two compounds hold particular pharmacological significance: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

THC constitutes the primary psychoactive compound in cannabis. Its lipophilic structure permits it to cross the blood-brain barrier, producing the characteristic intoxicating effect associated with marijuana use4. Female cannabis inflorescences yield the highest THC concentrations4. Based on THC content, cannabis is classified into three distinct chemotypes: drug type (chemotype I) with a THC/CBD ratio above 1, producing psychoactive effects; medium type (chemotype II) with a ratio close to 1, exhibiting low or no activity; and fiber type (chemotype III or hemp) containing less than 0.3 percent THC with a ratio below 1, cultivated for fiber and edible oil production4.

It is also important not to confuse plant-derived cannabis with synthetic cannabinoid products; Synthetic Marijuana Unmasked: The Deadly Truth Behind K2, Spice, and Paper Dope explores why K2, Spice, and other “fake weed” products can produce far more unpredictable toxicity than cannabis itself.

CBD operates through a substantially different pharmacological profile. This nonpsychoactive compound carries very low affinity for cannabinoid receptors and functions as a negative allosteric modulator4. Among its documented properties are analgesic, neuroprotective, anticonvulsant, antiemetic, spasmolytic, and anti-inflammatory effects4. CBD's activity as a CB2 receptor inverse agonist accounts in part for these anti-inflammatory actions4.

The Endocannabinoid System Explained

The human body synthesizes its own endogenous cannabis-like molecules through the endocannabinoid system (ECS) — a widespread neuromodulatory network with involvement across multiple physiological processes5. Several interconnected components constitute this signaling system.

Natural endocannabinoids function as the system's primary molecular messengers. N-arachidonoylethanolamine, commonly designated anandamide, was the first endocannabinoid identified6. The term derives from the Sanskrit word ananda, meaning bliss7. 2-arachidonoylglycerol (2-AG) serves as a second principal endocannabinoid4. Both molecules are arachidonic acid-derived compounds with affinity for cannabinoid receptors8.

The ECS incorporates cannabinoid receptor types 1 and 2 (CB1 and CB2), both members of the G-protein-coupled receptor (GPCR) family4. These receptors couple predominantly to inhibitory G proteins, suppressing adenylyl cyclase and voltage-sensitive calcium channels while stimulating mitogen-activated protein kinases and inwardly rectifying potassium channels5. Completing the system are enzymes responsible for endocannabinoid synthesis and metabolism, membrane transporters, and proteins governing receptor signal transduction4.

CB1 receptors concentrate most densely at neuron terminals throughout the nervous system — particularly the brain — with additional expression in the spinal cord and peripheral sensory nerve endings4. Hepatic tissue, adipose tissue, and skin also carry CB1 receptor populations5. CB2 receptors localize principally to immune tissues, including the spleen and tonsils, and to immune cells such as monocytes and B and T lymphocytes4. CB2 expression levels within immune cells exceed those of CB1 by a factor of 10 to 1009.

THC acts as a potent partial agonist at both CB1 and CB2 receptors, with dissociation constants of 10 and 24 nM respectively4. CB1 receptor binding mediates THC's psychoactive and analgesic effects, whereas CB2 receptor engagement governs its immunomodulatory actions4. CBD operates through distinct pathways, attenuating endocannabinoid degradation and potentially engaging receptors yet to be characterized10.

Across the nervous, endocrine, immune, cardiovascular, gastrointestinal, and reproductive systems, the ECS exerts broad modulatory influence9. Two principal enzymes govern endocannabinoid activity: fatty acid amide hydrolase (FAAH), which terminates anandamide signaling, and monoacyl glycerol lipase (MAGL), which degrades 2-AG5. For readers who want a broader framework for how receptor-level mechanisms translate into clinical risk, How Mechanistic Medical Toxicology Is Shaping Next-Generation Patient Care provides useful context on mechanism-based toxicology.

Cannabinoid Receptors in Reproductive Tissues

The presence of cannabinoid receptors throughout male and female reproductive anatomy establishes a direct biological pathway through which cannabis can interfere with fertility. CB1 receptors have been localized to the hypothalamus and anterior pituitary, and both CB1 and CB2 receptors are found within the ovary6. The ECS maintains a close functional relationship with the hypothalamic-pituitary-ovarian axis6.

Male reproductive anatomy harbors receptors and endocannabinoid ligands across the testis, seminal vesicles, corpus cavernosum, and spermatozoa8. CB1 receptor expression in human testis and spermatozoa suggests that ECS components modulate sperm function in ways relevant to fertilization capacity8. Within seminal vesicles, CB1, CB2, FAAH1, FAAH2, and G protein-coupled receptor 55 are all expressed in the epithelial layer, indicating ECS involvement in secretory regulation8.

Female reproductive tissues demonstrate equally extensive cannabinoid receptor distribution. CB1 receptors have been confirmed in the ovaries and endometrium6, while CB2 receptors are present in the ovarian cortex, medulla, and follicles6. Both receptor subtypes appear in preimplantation embryos, with CB2 mRNA detectable from the one-cell stage through the blastocyst stage11. This anatomical distribution forms the biological foundation for the reproductive disruptions examined in subsequent sections.

Does Cannabis Affect Male Fertility?

"There are many lab studies showing negative effects of marijuana on sperm. There are surprisingly few human trials, but they all demonstrate that cannabis use reduces sperm concentration, sperm motility (ability to swim), or both." — Doron Stember, MD, Assistant Professor of Urology at the Icahn School at Mount Sinai

Research examining cannabis and male fertility yields complex, occasionally contradictory findings across hormonal, cellular, and genetic parameters. The presence of cannabinoid receptors throughout male reproductive anatomy establishes a direct substrate for interference with normal reproductive function.

Impact on Testosterone and Luteinizing Hormone Levels

Early investigations into testosterone produced concerning data. A small case-control study found chronic marijuana users smoking 5–9 joints weekly had mean testosterone levels of 503 ng/100 mL compared to 742 ng/100 mL in non-users12, with those consuming 10 or more joints weekly falling further to 309 ng/100 mL13. Animal models corroborated these findings, as rats dosed acutely with THC at 10 mg/kg exhibited significant depression in testicular testosterone synthesis13.

Large-scale studies, however, have since complicated this picture. Data from men presenting to infertility clinics show no significant difference between ever-users and never-users upon multivariable analysis14. Serum testosterone concentrations actually run higher among men with more recent marijuana use, a relationship particularly pronounced in the 18–29 year age group14. Among men who have ever smoked marijuana, higher use intensity correlates with elevated serum testosterone, with 20 additional joint-years producing an adjusted difference of 8.22 ng/dL15.

Luteinizing hormone presents a more consistent pattern. Cannabis lowers LH levels across multiple independent studies1316, and the mechanism underlying this suppression became clearer when researchers used polyclonal antibodies to locate CB1 receptors within LH-secreting gonadotrophic cells of the anterior pituitary13. A primate study underscored the magnitude of this disruption — THC use associated with decreased testosterone and a greater than 50% reduction in testicular size, with severity escalating proportionally as THC dose increased17.

Changes in Sperm Count and Concentration

Across both animal and human investigations, cannabis use demonstrates consistent associations with reduced sperm count and concentration1318. Chronic marijuana users smoking 10 or more times weekly recorded significantly lower average sperm counts of 26.6 million per mL, compared to 67.9 million per mL among those smoking 5–9 times weekly13. The time course of this effect proved particularly instructive: 16 chronic marijuana smokers exposed to four weeks of high-dose marijuana showed measurable reductions in sperm count beginning 5–6 weeks after use was initiated13.

A Danish cohort study of 1,215 participants documented that men reporting marijuana use more than once weekly had 28% lower sperm concentration and 29% lower total sperm count relative to never-users13. A prospective study of 409 men presenting for fertility evaluation found that current users trended toward greater odds of falling below WHO reference values for total progressive motile count, though this did not reach statistical significance at p=0.0512.

Effects on Sperm Morphology and Motility

Morphological abnormalities constitute one of the most reproducible findings in this literature. Current marijuana users carried significantly elevated odds of below-WHO-reference semen volume, with an odds ratio of 2.7612, while cannabis smokers showed normal sperm morphology in only 2.26% of cells compared to 7.46% among non-smokers19. Population-level data from Jamaica, the Pacific Northwest, and the United Kingdom each independently associated marijuana use with increased risk of abnormal sperm morphology15.

Motility effects introduce a notable paradox. Cannabis-smoking groups exhibited 20.63% non-progressive motility against 34.40% in non-smoking groups19, and the proportion of immotile sperm ran significantly higher — 68.66% in cannabis users versus 51.73% in non-smokers19. Current users nonetheless showed significantly reduced odds of falling below WHO reference values for total motility, with an odds ratio of 0.47, which may suggest a counterintuitive protective effect12. In vitro evidence resolves some of this ambiguity, demonstrating dose-dependent detrimental outcomes: the 45% sperm fraction showed 28% reduced motility at 0.032 μM THC and 56% reduced motility at 4.8 μM13.

THC-Induced Alterations in Sperm DNA Methylation

Beyond conventional semen parameters, Duke University researchers identified that cannabis exposure is associated with altered DNA methylation profiles in sperm19. In experiments involving both rat models and a small human cohort, THC-related methylation changes were enriched in genes associated with two major pathways: Hippo Signaling and Pathways in Cancer. Higher urinary THC concentrations were associated with more pronounced methylation differences, suggesting a possible dose-related epigenetic signal. These findings do not prove that cannabis exposure causes disease in offspring, but they indicate that THC may affect sperm biology beyond standard measures such as count, motility, and morphology20. DNA integrity assessments further showed higher Acridine Orange scores among cannabis-smoking groups compared with non-smoking controls19, supporting the need for more research into cannabis, sperm DNA integrity, and preconception risk. This sperm-level toxicology also fits into a wider reproductive-toxicology discussion explored in AI-Driven Breakthrough in Male Infertility Raises New Questions for Reproductive Toxicology.

Does Cannabis Affect Female Fertility?

Female reproductive biology has received comparatively less investigative attention than male counterparts within the cannabis-fertility literature, yet the data that does exist reveals significant disruptions across multiple reproductive processes. Among patients presenting for infertility treatment, 13% report marijuana use21. The endocannabinoid system's documented presence throughout ovarian follicles, fallopian tubes, and endometrial tissue establishes direct anatomical pathways through which THC exerts its interference22.

THC Effects on Menstrual Cycle Regularity

Primate research conducted at Oregon Health & Science University furnished some of the earliest controlled evidence of THC-induced menstrual disruption. Healthy female nonhuman primates exposed to THC demonstrated measurably longer menstrual periods23, accompanied by corresponding elevations in follicle-stimulating hormone23. Critically, this relationship proved dose-dependent — as THC doses escalated from 0.625 mg/kg to 5 mg/kg, both menstrual cycle length and FSH concentrations increased in proportion2.

Human data supports these experimental observations. Women who smoked cannabis at least once in the three months preceding evaluation experienced delayed ovulation averaging 1.7 to 3.5 days relative to control individuals22. A prospective cohort study of 201 women in North Carolina further documented a significantly longer follicular phase among marijuana users15. Occasional users showed follicular phases approximately 3.5 days longer than non-users; frequent users, somewhat counterintuitively, exhibited phases 1.7 days longer24 — both associations surviving statistical adjustment for oral contraceptive use24.

Ovulation Dysfunction and Anovulatory Cycles

The disproportionate clustering of anovulatory cycles among cannabis users constitutes one of the more striking findings in this literature. Cannabis smokers represented only 15% of one study's population, yet accounted for 43% of all anovulatory cycles documented throughout the investigation22. Chronic marijuana users specifically demonstrated a higher proportion of anovulatory cycles relative to non-users24, with three of seven confirmed anovulatory cycles occurring exclusively within the marijuana-smoking cohort24.

Women who smoked marijuana within one year of attempting conception were twice as likely to experience infertility attributable to ovulatory dysfunction compared to non-users25. Further hormonal characterization revealed lower prolactin levels and marginally reduced peak luteinizing hormone concentrations in marijuana users24, alongside a measurably slower post-ovulatory rise in both estrogen and progesterone24.

Impact on Oocyte Quality and Maturation

A Nature Communications study examining over 1,000 ovarian fluid samples from IVF patients uncovered a clinically significant paradox. Follicular fluid THC concentration positively correlated with oocyte maturation rates3 — women with detectable THC levels produced eggs that matured at higher rates26. This apparent benefit, however, masked a serious underlying compromise: these same rapidly maturing oocytes generated fewer embryos with chromosomally normal complements26.

Laboratory investigation clarified the cellular mechanism responsible. Immature oocytes subjected to 24 hours of THC exposure in vitro exhibited markedly greater spindle abnormalities — the structural apparatus governing accurate chromosome segregation18. THC induced chromosome segregation errors and increased the frequency of abnormal spindle morphology3, producing a 9% net rise in aneuploidy rates3 alongside a disproportionately higher representation of complex aneuploidy3. Animal research using bovine oocytes treated at both therapeutic and recreational THC concentrations demonstrated significantly decreased connexin gene expression, a molecular marker associated with impaired embryo development27.

Cannabis Use and In Vitro Fertilization Outcomes

Outcomes data from assisted reproduction programs reinforces the laboratory-derived evidence. A prospective study of 221 couples found that women who had smoked marijuana within one year prior to IVF retrieved 25% fewer oocytes2, and these couples experienced 28% fewer fertilized oocytes overall2. Among women undergoing assisted reproductive technology who tested positive for beta-human chorionic gonadotropin, marijuana smokers at enrollment carried more than double the adjusted probability of pregnancy loss — 54% versus 26%2.

THC-positive patients demonstrated significantly lower embryo euploidy rates, with only 60% achieving chromosomally normal status compared to 67% in THC-negative matched groups3. Statistical modeling retained THC positivity as a significant independent variable: THC-positive status decreased the odds of achieving a blastulation rate at or above 50% (odds ratio 0.45)3 and reduced the odds of attaining a euploidy rate above 60% (odds ratio 0.47)3. The degree of underreporting identified in this context warrants particular attention — when THC metabolites were quantified directly from follicular fluid, 73% of positive patients had not disclosed cannabis consumption on their intake questionnaires3.

Does Cannabis Affect Hormones in Females and Males?

The hypothalamic-pituitary-gonadal axis represents the primary site where cannabinoid receptors exert control over reproductive hormone cascades. Key components of the endocannabinoid system reside in the hypothalamus, pituitary, and reproductive organs, positioning them to interfere with normal endocrine function28.

Disruption of the Hypothalamic-Pituitary-Gonadal Axis

The HPG axis functions as a tightly regulated endocrine system. Gonadotropin-releasing hormone, secreted in a pulsatile pattern from the hypothalamus, serves as the prime modulator of downstream reproductive hormone activity28. This peptide hormone acts through receptors in the anterior pituitary to govern the release of two critical gonadotropins: low-frequency GnRH pulses stimulate follicle-stimulating hormone release, while high-frequency pulses stimulate luteinizing hormone release29. GnRH release frequency remains constant in males; in females, however, pulse frequency increases substantially at ovulation, generating the LH surge that triggers egg release29.

CB1 receptor activation suppresses GnRH release at the level of the hypothalamus. Experiments conducted on isolated hypothalamic tissue demonstrated THC-induced suppression of stimulated — though not basal — GnRH release29. Hypothalamic GnRH neurons themselves produce and secrete at least two endocannabinoids, 2-AG and anandamide, both of which activate hypothalamic CB1 receptors to inhibit GnRH release and regulate processes spanning puberty onset, ovulation, lactational infertility, and menopause28.

Chronic bhang administration in male mice reduced pituitary expression of GnRH receptors29. The reproductive toxicity of cannabis therefore stems primarily from THC's capacity to alter HPG axis homeostasis28. Prolonged THC administration significantly decreased spermatogenesis, a consequence attributed to excessive activation of CB receptors distributed across the central nervous system and testis28.

Follicle-Stimulating Hormone (FSH) Suppression

Studies examining acute and chronic marijuana exposure on circulating FSH levels in males have generally found minimal effects, with no alteration in FSH response to exogenous GnRH2. Nonetheless, chronic marijuana use does reduce circulating FSH concentrations in certain human studies30, and THC, cannabinol, and cannabidiol have each been shown to lower both testosterone and FSH levels concurrently30. The clinical consequences of FSH suppression in cycling females are considerable — reductions in ovarian follicle development, oocyte maturation, and gonadal steroid production may produce anovulatory cycles and compromised fertility31.

Among men, those who had ever smoked marijuana exhibited significantly lower serum FSH concentrations relative to never-smokers32. Furthermore, more intensive marijuana use produced dose-dependent, non-linear effects on gonadotropin production32.

Luteinizing Hormone (LH) Level Changes

The inhibitory effect of cannabis on LH is one of the more robustly documented hormonal findings in this field. Plasma LH levels declined significantly within 60 minutes following low-dose THC administration at 0.5 mg/kg body weight in male rats2. Daily marijuana users aged 19 to 20 years demonstrated significantly lower serum LH concentrations and an attenuated LH response to exogenous GnRH33, while plasma LH was significantly depressed following active marijuana cigarette use compared to placebo2.

Systemic and intracerebroventricular anandamide administration reduced circulating LH and testosterone levels in mice28. This suppression operates through CB1 receptor activation on GnRH neurons, leading to inhibition of pulsatile GnRH release28. Confirmation of the mechanistic pathway came from knockout studies: anandamide reduced LH concentrations in wild-type mice but not in CB1 receptor knockout animals, establishing CB1R as the principal site of cannabinoid-induced LH suppression29.

Estrogen and Progesterone Fluctuations in Women

THC administration blocks both ovulation and the LH surge in rat models29. High-dose cannabis extract decreases progesterone concentrations during the luteal phase in mice29, and THC treatment administered to monkeys during the follicular phase suppresses ovulation alongside reductions in circulating LH, FSH, and estrogen29. A single acute inhalation of one gram of marijuana suppressed plasma LH during the luteal phase of the human menstrual cycle, though no such effect appeared during the follicular phase31. A single intramuscular dose of 2.5 mg/kg THC administered during the mid-luteal phase similarly decreased circulating progesterone in rhesus monkeys31.

Daily 2.5 mg/kg THC administration throughout the follicular phase disrupted follicle development, reduced estrogen and progesterone synthesis, blocked the LH surge, and prevented ovulation31. Chronic THC administration sustained across consecutive menstrual cycles produced transient HPO axis disruption, with thrice-weekly dosing at 2.5 mg/kg robustly suppressing serum estradiol, progesterone, LH, and prolactin31. Of particular note, female rats possess both different endocannabinoid concentrations and more sensitive receptors than males in key brain regions, with receptor sensitivity varying significantly across the menstrual cycle34. Because endocrine toxicology often overlaps with reproductive health, Hidden Signs of Cortisol Poisoning During Menopause: What Doctors Won't Tell You may also help readers understand how hormonal disruption can present outside classic poisoning scenarios.

Cannabis Use During Pregnancy and Conception

Risks of Prenatal Cannabis Exposure

Cannabis use among pregnant women climbed from 3% in 2002 to 7% in 201735, and by 2019, 5.4% of pregnant women reported active use35. Self-reported prevalence rates of 2% to 5% almost certainly underestimate actual consumption, given the well-documented reluctance of patients to disclose substance use to their obstetric providers36. Particularly striking is the finding that 34% to 60% of individuals who use marijuana continue doing so throughout pregnancy37. Among those who do, 14% reported consuming one or more joints daily during the first trimester alone, with rates declining only modestly to 5.3% and 5.0% in the second and third trimesters respectively36.

The clinical consequences of prenatal cannabis exposure are measurable and serious. A cohort study of 316,722 pregnancies identified prenatal cannabis use as a significant risk factor for gestational hypertension (adjusted relative risk 1.17)38, preeclampsia (aRR 1.08)38, and placental abruption (aRR 1.19)38. Gestational weight gain deviating from established guidelines — both insufficient (aRR 1.05)38 and excessive (aRR 1.09)38 — also increased. Mechanistically, cannabinoids cross the placenta and bind directly to placental cannabinoid receptors, inhibiting epithelial layer migration in human placental amnion tissue and disrupting both endogenous cannabinoid and estrogen signaling pathways38.

Association with Preterm Birth and Low Birth Weight

A meta-analysis drawing from 16 studies and 59,138 patients quantified the neonatal burden associated with prenatal cannabis exposure. The risk of birth weight falling below 2,500 grams more than doubled (RR 2.06)37, while the likelihood of delivering a small-for-gestational-age infant rose by 61% (RR 1.61)37. Mean birth weight decreased by 112.30 grams on average37, with studies isolating continued users demonstrating reductions of 277 grams — compared to 156 grams among women who used cannabis only in early pregnancy36.

Preterm delivery risk increased by 28% (RR 1.28)37, corroborated by two independent studies reporting spontaneous preterm birth adjusted odds ratios of 2.34 and 2.28 respectively39. NICU admission rates rose 38% (RR 1.38)37, while Apgar scores at one minute decreased by 0.26 points37 and infant head circumference was reduced by 0.34 cm37 — findings that collectively point to a pattern of fetal growth compromise rather than isolated adverse events.

Effects on Fetal Neurodevelopment

The neurodevelopmental consequences of prenatal cannabis exposure extend well beyond the neonatal period. Exposure following the mid-first trimester associates with attention, social, and behavioral difficulties that persist into early adolescence at ages 11 to 12 years35. At birth, affected newborns present with a withdrawal-like syndrome characterized by increased startles, tremors, and reduced habituation to light stimuli36. These early neurological signs evolve into measurable deficits in verbal and visual reasoning, hyperactivity, attention problems, and impulsivity that manifest during the preschool years and persist throughout formal schooling36.

Experimental data from nonhuman primate models provides mechanistic context for these clinical observations. All fetal brains examined following THC exposure demonstrated acute ischemic changes, most prominently in the cerebellum, with histological evidence of ischemic white matter injury40. Focal Purkinje cell dropout further indicated both earlier cell death and longer-term structural injury40. Rodent models corroborated these findings, with exposed embryos exhibiting smaller bodies and enlarged brain ventricles — an indicator of aberrant neurological development — alongside brain volume reductions that persisted into adulthood41.

Placental Function and Cannabis Compounds

THC exerts direct effects on placental physiology at the molecular level. Gestational THC exposure reduced placental GLUT1 expression — the primary glucose transporter — by approximately 35% in the labyrinth layer42. This reduction occurred alongside a decreased fetal-to-placental weight ratio and preceded symmetrical growth restriction at birth42, suggesting that impaired glucose transport represents a primary pathway through which THC restricts fetal growth.

Histological examination of placentas from cannabis-smoking women revealed increased syncytiotrophoblast knots and fibrin exudation in the villous stroma43, structural changes with the potential to impair oxygen, nutrient, and waste product exchange across the placenta. THC further attenuated syncytialization and reduced trophoblast capacity for migration and invasion43 — processes essential to normal placental implantation and vascular remodeling. Correspondingly, pregnant women who smoked cannabis presented with narrower placental vascular networks43, a finding associated with downregulation of angiogenesis and blood vessel formation43, compounding the functional deficits already imposed at the cellular level.

Can Cannabis Affect Fertility Through Chromosome Errors?

"It’s important that patients try to abstain from cannabis use when trying to conceive, but for those that cannot, this still offers an opportunity for harm reduction by reducing the amount they’re using to mitigate adverse outcomes to themselves and their fertility, their reproductive health, and their babies." — Jamie Lo, Physician-researcher, associate professor of obstetrics and gynecology at Oregon Health & Science University

Chromosome segregation errors during oocyte maturation constitute one of the more alarming cellular mechanisms through which cannabis undermines female fertility. Confocal microscopy investigations examining meiotic spindle organization and chromosome alignment have uncovered profound THC-induced disturbances at the subcellular level — disturbances that carry direct clinical consequences for embryo viability.

Spindle Morphology Abnormalities in Oocytes

Healthy meiotic spindles present as bipolar, barrel-shaped microtubule structures with chromosomes precisely aligned along the metaphase plate44. Pathological spindles, by contrast, display multipolar configurations, microtubule disorganization, and chromosomal misalignment44. THC exposure produced a marked escalation in spindle abnormalities: control oocytes registered 42% abnormal spindles, whereas high-dose THC treatment elevated this figure to 92%44. The statistical significance of this increase (p=0.0272) establishes a clear dose-dependent relationship between THC concentration and structural spindle disruption44.

Increased Aneuploidy Rates in Embryos

Polar body biopsy combined with low-pass whole genome sequencing provided direct quantification of chromosomal errors following THC exposure. Both low- and high-dose THC treatment produced a 9% rise in aneuploidy rates, shifting from 39% in control oocytes to 48% in THC-exposed groups44. Clinical data from IVF cycles corroborated these laboratory observations: embryo euploidy rates declined significantly among THC-positive patients, with only 60% achieving chromosomally normal status compared to 67% in THC-negative patients345. THC-positive patients consequently faced reduced odds of attaining euploidy rates above 60%44.

Complex Chromosomal Abnormalities

Complex aneuploidy — defined as the concurrent gain or loss of three or more chromosomes44 — appeared exclusively within THC-exposed oocytes. Control groups recorded 0% complex aneuploidy, while THC treatment groups demonstrated rates of 42%4446. This finding carries particular clinical weight, given that complex chromosomal errors characteristically produce arrested embryo development or early-pregnancy loss rather than viable implantation. Accurate chromosome segregation during oocyte maturation yields euploid embryos with the greatest statistical probability of establishing a successful pregnancy44. The spindle disorganization and chromosomal misalignment attributable to THC fundamentally impair this process, reducing fertility outcomes for cannabis-using patients across both natural conception and assisted reproductive technology cycles.

Time to Pregnancy and Fertility Treatment Outcomes

Reduced Fecundability in Cannabis Users

Natural conception timelines extend measurably when cannabis use is present. A 1990 investigation found women who smoked marijuana within one year of attempting conception were twice as likely to experience infertility attributable to ovulatory dysfunction (RR 2.1)2. A subsequent secondary analysis of women with prior first-trimester pregnancy loss further found preconception marijuana use associated with reduced fecundability (aOR 0.59)15. Conflicting evidence does exist, however: a 4,194-participant prospective cohort study found little association between female marijuana use and spontaneous conception rates after controlling for confounders2, reflecting the methodological complexity that characterizes much of this research literature.

Impact on Assisted Reproductive Technology Success Rates

The adverse effects of cannabis use become particularly pronounced within assisted reproductive technology settings, where objective clinical measurements allow for more precise quantification. Women who smoked marijuana within one year prior to IVF had 25% fewer oocytes retrieved2, with these couples correspondingly producing 28% fewer fertilized oocytes2. Among women undergoing ART who tested positive for beta-human chorionic gonadotropin, marijuana smokers at enrollment demonstrated more than double the adjusted probability of pregnancy loss at 54% versus 26% in non-users47. These figures align with the chromosomal disruption data discussed in prior sections, where THC-induced spindle abnormalities and aneuploidy elevations provide a plausible biological mechanism for the elevated loss rates observed clinically.

Embryo Euploidy Rates in THC-Positive Patients

Chromosomal integrity at the embryo level represents a further domain of measurable impairment. THC-positive patients exhibited significantly lower embryo euploidy rates at 60% compared to 67% in matched controls3, with THC positivity independently decreasing the odds of achieving a blastulation rate above 50% (odds ratio 0.45) and a euploidy rate above 60% (odds ratio 0.47)3. Of particular clinical significance, follicular fluid analysis identified a THC positivity rate of only 6%3, a figure that stands in stark contrast to the 23% of female patients who self-reported recreational cannabis consumption within the preceding year3. This discrepancy between biochemically confirmed exposure and patient disclosure underscores the degree to which cannabis use remains systematically underreported in fertility treatment settings, complicating both clinical assessment and the accurate attribution of adverse outcomes. The gap between self-report and biological testing is a recurring challenge in toxicology, and Drug Screens Lie: A Clinician’s Guide to Interpreting Toxicology Tests Safely explains why test interpretation must always be tied to clinical context.

Clinical Recommendations for Couples Trying to Conceive

Evidence-Based Guidelines from Medical Organizations

Major medical organizations have reached clear consensus against cannabis use during the preconception period. The American College of Obstetricians and Gynecologists now recommends universal screening for cannabis use across prepregnancy, pregnancy, and postpartum periods48. Health Canada explicitly states that individuals attempting pregnancy should avoid cannabis altogether49, a position echoed by the Society of Obstetricians and Gynecologists of Canada, which advises healthcare providers to ask women periodically about substance use, including cannabis49. ACOG further stipulates that no medical indication exists for cannabis use during pregnancy or the postpartum period4850. Critically, screening protocols should employ non-punitive, non-stigmatizing methods to encourage disclosure rather than relying on biological testing alone51[381]. This is especially important in pregnancy-related toxicology, where How Drug Testing Harms Pregnant Women and Their Families? discusses how poorly designed drug-testing policies can damage trust, disclosure, and clinical care.

Cannabis Cessation Strategies for Preconception

Male patients require a minimum cessation period of 74 to 90 days before attempting conception, a timeline corresponding to one complete spermatogenesis cycle5253. This interval allows sperm parameters — including concentration, motility, and morphology — to recover from THC-related disruption. Clinicians may draw upon motivational interviewing alongside screening, brief intervention, and referral to treatment protocols to support patients through cessation51. Collaborative clinical conversations, wherein providers acknowledge patients' reasons for use while offering evidence-based information about reproductive risks, foster informed decision-making without alienating those who may be reluctant to disclose51.

When to Seek Fertility Evaluation

Couples younger than 35 years should pursue formal fertility evaluation after 12 months of unprotected intercourse without conception5455. Women aged 35 and older warrant earlier assessment, with evaluation recommended following six months of unsuccessful attempts54[372]56. Women aged 40 and above should initiate discussions with a reproductive specialist without delay54.

Current Limitations and Future Research

Although the evidence linking cannabis to reproductive outcomes is growing, several important limitations remain. Many human studies are observational, retrospective, or cross-sectional, which makes it difficult to prove causation [2,15]. Confounding factors such as tobacco use, alcohol use, other substance exposure, nutrition, body mass index, socioeconomic status, and baseline fertility status are not always fully controlled [2,15,37,38].

Dose-response relationships are also poorly characterized. Cannabis products vary widely in THC concentration, CBD content, route of administration, frequency of use, and duration of exposure [1,3,4]. A person using high-potency THC daily may not have the same reproductive risk profile as someone using cannabis occasionally.

The evidence base is also stronger for THC than for CBD. Although CBD has distinct pharmacology and is widely marketed as non-intoxicating, its direct effects on human fertility remain insufficiently studied [4,10]. Similarly, several sperm epigenetic studies involve small sample sizes, including the Duke human cohort of 24 male subjects [20], and IVF-based findings may not generalize to natural conception [3].

Future research should clarify dose, timing, route, sex-specific effects, reversibility after cessation, CBD-specific outcomes, and whether observed laboratory changes translate into clinically meaningful differences in pregnancy and live-birth rates.

Conclusion

All things considered, the evidence demonstrates that cannabis significantly disrupts both male and female fertility through multiple mechanisms. THC interferes with the hypothalamic-pituitary-gonadal axis, reducing sperm quality in men and causing ovulatory dysfunction in women. For this reason, couples attempting conception face reduced success rates, chromosome abnormalities in embryos, and increased pregnancy complications. As a result, major medical organizations now recommend complete cannabis cessation during the preconception period. We encourage you to discuss these findings with your healthcare provider if you're planning pregnancy. The good news is that stopping cannabis use allows the reproductive system to recover, offering couples the best chance at healthy conception and pregnancy outcomes.

FAQs

Q1. How does marijuana use impact reproductive hormones in men and women? Cannabis use can disrupt the release of key reproductive hormones including follicle-stimulating hormone (FSH) and luteinizing hormone (LH). In men, it may affect testosterone levels and sperm parameters, while in women it can interfere with menstrual cycle regularity and ovulation processes.

Q2. Can cannabis use reduce sperm quality in men? Yes, research shows that cannabis use is associated with reduced sperm count, decreased sperm concentration, and abnormal sperm morphology. Studies have found that men who use marijuana regularly may have significantly lower sperm counts and reduced sperm motility compared to non-users.

Q3. Does marijuana affect a woman's ability to ovulate? Cannabis use can cause ovulation dysfunction and anovulatory cycles. Women who smoke marijuana may experience delayed ovulation, longer follicular phases, and a higher proportion of cycles without ovulation, which can significantly impact fertility.

Q4. How long should couples stop using cannabis before trying to conceive? Men should stop cannabis use for at least 74 to 90 days before attempting conception to allow for one complete sperm production cycle. Women should also discontinue use during the preconception period, as recommended by major medical organizations including the American College of Obstetricians and Gynecologists.

Q5. Does cannabis use affect IVF success rates? Yes, cannabis use can negatively impact assisted reproductive technology outcomes. Women who used marijuana within one year prior to IVF had 25% fewer eggs retrieved and 28% fewer eggs fertilized. Additionally, THC-positive patients showed lower embryo euploidy rates and reduced odds of achieving successful blastulation rates.